RUNX2 and prostate cancer: CT/MRI-guided biopsy differentiates osteoblastic/osteolytic prostate cancer metastases, molecular markers (ERG fusion, RUNX2, Wnt dysregulation) indicate osteo-tropic mechanisms correlatable with imaging.